Related Experiment Video
Updated: Mar 18, 2026
08:13
Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
72.4K
Statin-induced diabetes: incidence, mechanisms, and implications
1Clinical Research and Adult Diabetes Sections, Joslin Diabetes Center, Department of Medicine, Harvard Medical School, Boston, MA, USA.
F1000Research
|July 14, 2016
Summary
Statin use may slightly increase new-onset diabetes risk, particularly in those with metabolic syndrome. Lifestyle adherence is crucial for prevention, and the cardiovascular benefits of statins outweigh this risk.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Background:
- Randomized controlled trials and observational studies suggest statins are associated with a modest increase in new-onset diabetes.
- Risk factors for statin-associated diabetes include baseline diabetes risk, metabolic syndrome, statin intensity, genetics, and lifestyle adherence.
Purpose of the Study:
- To review the evidence on statin therapy and the risk of new-onset diabetes.
- To explore potential mechanisms of statin-induced diabetogenesis.
- To contextualize this risk within the overall cardiovascular benefit of statins.
Main Methods:
- Meta-analyses of statin trials.
- Longitudinal population-based studies.
- Review of existing literature on mechanisms of action.
Main Results:
- Statin initiation is linked to a modestly increased risk of new diabetes.
- Risk factors include metabolic syndrome, higher statin intensity, and genetic predispositions.
- Limited data suggest statins may modestly worsen glycemic control in individuals with pre-existing diabetes or glucose intolerance.
- Potential mechanisms involve impaired insulin sensitivity and beta-cell function, possibly related to cholesterol synthesis inhibition.
Conclusions:
- The cardiovascular benefits of statin therapy generally outweigh the risk of new-onset diabetes.
- Lifestyle modifications are critical for mitigating diabetes risk in patients taking statins.
- Further research is needed to fully elucidate the mechanisms of statin-induced diabetes, including potential pro-inflammatory effects under dysmetabolic conditions.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
934
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
934
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
830
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
830
01:20Pathophysiology of Diabetes
4.2K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.2K
01:06Oral Hypoglycemic Agents: Glinides
879
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
879
01:22Diabetes Mellitus: Overview and Type I Subtype
5.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
5.8K